ETOPOSIDE
NK-Cell Leukemia
New York Medical CollegeSmall moleculeEarly Phase 1Active
C
39/ 100
Provisional rating · Methodology v0.2
Rating breakdown
- Clinical Evidence
- 24/ 100
- Competitive Position
- 95/ 100
Competitive context
18 Active assets in the NK-Cell Leukemia cohort.
| Asset / Sponsor | Phase | Rating |
|---|---|---|
Cyclophosphamide The Affiliated Hospital of Xuzhou Medical University | Phase 2 | B |
Thiotepa St. Jude Children's Research Hospital | Phase 2 | CCC |
Anti-Thymoglobulin, Rabbit St. Jude Children's Research Hospital | Phase 2 | CCC |
Blinatumomab St. Jude Children's Research Hospital | Phase 2 | CCC |
Fludarabine The Affiliated Hospital of Xuzhou Medical University | Phase 2 | CCC |
View all 21 →
Same molecule, other indications
ETOPOSIDE is also rated in:
Are you the sponsor?
Submit your data room for a Verified Rating. The public-data rating remains visible alongside.
Contact →